Influence of prothrombin complex concentrates on plasma coagulation in critically ill patients.
Intensive Care Med
; 25(10): 1105-10, 1999 Oct.
Article
em En
| MEDLINE
| ID: mdl-10551966
ABSTRACT
OBJECTIVE:
To evaluate thrombogenicity of prothrombin complex concentrates (PCCs) in critically ill patients.DESIGN:
Prospective clinical study.SETTING:
Medical intensive care unit at a university hospital. PATIENTS 16 consecutive patients suffering from acquired deficiencies of coagulation factors and with either overt bleeding from any site or a planned invasive procedure.INTERVENTIONS:
2000 factor IX units of PCCs intravenously. MEASUREMENTS ANDRESULTS:
Prothrombin time (PT), activated partial prothrombin time, fibrinogen, platelet count, plasma levels of coagulation factors II, V, VII, VIII, IX, X, antithrombin, protein C, thrombin-antithrombin complex (TAT), prothrombin fragment F(1+2), and the fibrin degradation product D-dimer were measured prior to and 1, 3, and 24 h after administration of PCCs. PT as well as coagulation factors II, VII, IX, and X, TAT, and F(1+2) showed a significant increase after administration of PCCs. All other parameters remained unchanged.CONCLUSIONS:
Administration of PCCs induces thrombin generation. No evidence for induction of disseminated intravascular coagulation in biochemical terms could be found. When rapid correction of acquired coagulation factor disturbances is warranted, the use of PCCs seems reasonable, but the elevated risk of intravascular thrombus formation should be kept in mind.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Fatores de Coagulação Sanguínea
/
Transtornos de Proteínas de Coagulação
Tipo de estudo:
Clinical_trials
/
Observational_studies
/
Risk_factors_studies
Limite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Intensive Care Med
Ano de publicação:
1999
Tipo de documento:
Article
País de afiliação:
Áustria